Inivata lung cancer test launched in the US
Inivata, a Cambridge UK leader in liquid biopsy, reports that NeoGenomics, Inc– its strategic commercialisation partner in the United States for the InVisionFirst®-Lung liquid biopsy – has commercially launched the test in the US.
InVisionFirst-Lung is a ctDNA next-generation sequencing liquid biopsy assay testing 37 genes relevant to the care of advanced non-small cell lung cancer.
The test covers all National Comprehensive Cancer Network guideline-recommended genomic drivers with FDA-approved targeted therapies for NSCLC.
InVisionFirst-Lung results are delivered within seven calendar days and the test is covered by Medicare and various private insurance payers for patients with advanced NSCLC meeting certain clinical criteria.
Nasdaq-quoted NeoGenomics is a leading US-based cancer diagnostics and services company. As an established player in the field with significant commercial reach and scale, it is well placed to advance the commercialisation of InVisionFirst-Lung.
NeoGenomics has an extensive direct national sales team that serves the needs of pathologists, oncologists, academic centres, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organisations throughout the United States.
Clive Morris, CEO of Inivata, said: “This is a significant step in the commercialisation of InVisionFirst-Lung. NeoGenomics has proven capabilities in this field and, since signing our agreement in May, I have been hugely impressed by their commitment to bring this important technology to clinicians and patients in the US.
“Our teams have been working closely together to prepare for this launch and I look forward to our continued collaboration.”